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We have isolated stably transfected mouse embryonic fibroblast cell lines that inducibly express either the mature encephalomyocarditis virus
(EMCV) or hepatitis A virus (HAV) 3C protease and have used these cells to demonstrate that both proteins are subject to degradation in vivo by
the ubiquitin/26S proteasome system. The detection of 3C protease expression in these cells requires inducing conditions and the presence of one
of several proteasome inhibitors. Both 3C proteases are incorporated into conjugates with ubiquitin in vivo. HAV 3C protease expression has
deleterious effects on cell viability, as determined by observation and counting of cells cultured in the absence or presence of inducing conditions.
The EMCV 3C protease was found to be preferentially localized to the nucleus of induced cells, while the HAV 3C protease remains in the
cytoplasm. The absence of polyubiquitinated EMCV 3C protease conjugates in nuclear fraction preparations suggests that localization to the
nucleus can protect this protein from ubiquitination.
© 2006 Elsevier Inc. All rights reserved.Keywords: 3C protease; Encephalomyocarditis; Hepatitis A; Picornavirus; Proteasome; Proteolysis; UbiquitinIntroduction
Successful replication of Picornaviridae family members
depends to a large extent upon the ability of these viruses to
commandeer host cell protein synthesis machinery, generate
viral proteins at the required concentrations in a coordinated
manner, and limit the ability of cellular processes to interfere
with viral RNA replication, protein production, and virion
assembly (for reviews see Bedard and Semler, 2004; Lloyd,
2005; Weidman et al., 2003). The entire genome of these
positive-sense RNA viruses is translated via a cap structure-
independent, IRES-directed mechanism as a single, approxi-
mately 250 kDa concatenated polyprotein that is processed
primarily by viral genome-encoded proteases. In addition to⁎ Corresponding author. Department of Chemistry, Bates College, Lewiston,
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doi:10.1016/j.virol.2006.10.043their essential involvement in the maturation of functional viral
proteins, including themselves, from polyprotein precursors, it
is becoming apparent that picornaviral proteases are key players
in establishing an intracellular environment that can support
virus replication. Several examples of picornaviral 2A and 3C
protease-mediated cleavage of nuclear and cytoplasmic proteins
required for host cellular transcription and mRNA translation
have been reported (Amineva et al., 2004; Belsham et al., 2000;
Devaney et al., 1988; Etchison et al., 1982; Falk et al., 1990;
Haghighat et al., 1996; Hambidge and Sarnow, 1992; Joachims
et al., 1999; Kerekatte et al., 1999; Krausslich et al., 1987;
Kuyumcu-Martinez et al., 2004; Sommergruber et al., 1994;
Tesar and Marquardt, 1990; Weidman et al., 2003; Ziegler et al.,
1995a,1995b), and 3C protease activity has been shown to
disrupt NF-κB-dependent innate immune responses and induce
caspase-dependent apoptosis as part of the infectious cycle of
many picornaviruses (Barco et al., 2000; Deszcz et al., 2005;
Neznanov et al., 2005).
Important factors which must impact the effectiveness of
picornaviral protease function are the absolute and relative
concentrations of these enzymes during various stages of the
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as part of the initial polyprotein requires that differences in
cellular concentrations of mature viral proteins be determined
by differences in maturation rates and in the rates of their
subsequent degradation. For example, we have shown that the
rapid degradation rate of mature EMCV 3C protease in virus-
infected cells can be a factor in determining its concentration
relative to other viral proteins (Lawson et al., 1989). The
inability to detect mature 3C protease in hepatitis A virus
(HAV)-infected cells (Jia et al., 1991) may also be explained by
a rapid in vivo turnover rate. We have found that both the
EMCVand HAV 3C proteases and certain of their 3C protease-
containing polyprotein precursors are substrates in vitro for
rapid, selective degradation by the ubiquitin/26S proteasome
system (Gladding et al., 1997; Lawson et al., 1994, 1999;
Losick et al., 2003). This system selectively tags substrate
proteins at primary amines with polymeric ubiquitin chains
through an enzymatic cascade requiring the ubiquitin-activating
enzyme (E1) and specific ubiquitin-conjugating protein and
ubiquitin–protein ligase (E2/E3) pairs. The resulting polyubi-
quitin–protein conjugates are recognized and degraded by the
26S proteasome complex (for reviews see Ciechanover et al.,
2000; DeMartino and Slaughter, 1999; Glickman and Ciechan-
over, 2002; Hendil and Hartmann-Petersen, 2004; Passmore
and Barford, 2004; Pickart, 2001). While in vitro experiments
have revealed details about interactions between the EMCVand
HAV 3C proteases and the ubiquitin-conjugating pathway
proteins that recognize them (Lawson et al., 1999, 2001), direct
evidence that the ubiquitin/26S proteasome system is respon-
sible for degrading these proteins in vivo has been lacking. It is
possible that association with other proteins, compartmentaliza-
tion, or other events sequesters the 3C proteases from the
cellular ubiquitinating machinery in vivo.
We report here the results of experiments designed to
determine whether the EMCV and HAV 3C proteases are
degraded in vivo by the ubiquitin/26S proteasome system and
whether the accumulation of these proteins in cells produces
obvious cytotoxic effects. We prepared mouse embryonic
fibroblast cell lines stably transfected with cloned genes coding
for either the EMCV or HAV 3C protease under the control of
the inducible synthetic heterodimeric ecdysone/retinoid-X-
receptor protein. We found that the presence of a proteasome
inhibitor was required for expressing detectable levels of both
proteins under inducing conditions and for maintaining the
proteins at detectable levels for extended periods of time. High
molecular mass proteins precipitated from induced whole cell
lysates using anti-3C protease antibodies were shown to cross-
react with anti-ubiquitin antibodies. These results demonstrate
that the 3C proteases are ubiquitinated and degraded by the
ubiquitin/26S proteasome system in vivo. The requirement for a
proteasome inhibitor to accumulate the expressed 3C proteins
complicated our attempts to monitor 3C protease-dependent
cytotoxicity, because these inhibitors produce predictable and
unrelated cytotoxic effects on their own. We did, however,
observe greater cytotoxic effects on induced cells expressing the
HAV 3C protease than on uninduced or control cell lines. An
examination of nuclear and cytoplasmic fractions of inducedcells revealed the localization of significant quantities of mature
EMCV 3C protease to the nucleus, where it appears to be
sequestered from ubiquitination. In contrast, the HAV 3C
protease remained localized in the cytoplasm.
Results
The EMCV and HAV 3C proteases are degraded in vivo by the
ubiquitin/26S proteasome system
Stably transfected, inducible mouse cell lines that express the
EMCVor HAV 3C proteases were prepared for the experiments
described in this study using the two-plasmid Complete Control
inducible mammalian expression system (Stratagene), which
includes the pERV3 and pEGSH plasmids. For cells transfected
with both plasmids, transcription is induced upon recruitment of
a transcriptional co-activator to the receptor protein/promoter
complex following binding of ecdysone (or the hormone analog
ponasterone A) by the receptor protein (Chen et al., 1996; No
et al., 1996). NIH3T3 cells stably transfected with pERV3 and
confirmed to constitutively express the ecdysone/retinoid-X-
receptor (ER-NIH3T3 cells) were subsequently transfected with
pEGSH constructs carrying sequences encoding either the
EMCV 3C protease with an N-terminal methionine or the HAV
3C protease with an N-terminal methionine–glycine. Over 100
colonies were selected from each transfection for their ability to
survive simultaneous G418 and hygromycin challenge. Of
these, 40–50 colonies from each transfection were screened by
Western blot analysis of whole cell lysates for the expression of
the 3C proteins under inducing conditions.
As expected, 3C protease could be not be detected in any of
the isolated transfected cell lines in the absence of ponasterone
A treatment. In addition, none of the hygromycin-resistant cell
lines produced detectable 3C protease levels under inducing
conditions in the absence of one of several specific, membrane-
permeable inhibitors of the 26S proteasome. Five different
proteasome inhibitors were tested, including the reversible
z-Leu-Leu-Leu-CHO (MG132), z-Leu-Leu-Phe-CHO (z-LLL-
CHO), z-Leu-Leu-Nva-CHO (MG115), and z-Leu-Leu-Leu-B
(OH)2 (MG262), and the irreversible inhibitor clasto-lactacystin
β-lactone (lactacystin). Each of these compounds has inhibitory
activity toward 26S proteasome-dependent protein degradation
in vivo with varying IC50 values (Craiu et al., 1997; Dick et al.,
1997; Fenteany and Schreiber, 1998; Lee and Goldberg, 1996,
1998; Lopes et al., 1997; McCormack et al., 1997; Orlowski et
al., 1997; Palombella et al., 1994; Rock et al., 1994; Schauer et
al., 1998). Lactacystin, an inhibitor of the β-catalytic subunit of
the proteasome, has been recognized to be particularly specific
for inhibiting proteasome-dependent catalysis (Craiu et al.,
1997; Dick et al., 1997; Fenteany and Schreiber, 1998). All of
these inhibitors were found to allow both the EMCV and HAV
3C proteases to accumulate to detectable levels in cells under
inducing conditions. This provides a strong indication that both
proteins are highly susceptible to in vivo degradation by the
proteasome. Approximately 10% of the isolated colonies
screened demonstrated significant levels of either 3C protease
expression in the presence of inducing conditions and a
Fig. 1. Proteasome inhibitor requirement for expressed 3C protease detection. (A and B) Time course of induced EMCV 3C protease (panel A) and HAV 3C protease
(panel B) expression in presence of proteasome inhibitors. pEGSH-E3C- or pEGSH-H3C-transfected cells were placed in medium containing ponasterone A and either
25 μMMG132 or 100 μM z-LLF-CHO and incubated at 37 °C in 5% CO2. The cells were harvested and lysed at the indicated times and 50 μg of lysate protein from
each sample was analyzed by SDS-PAGE and Western blotting using either anti-EMCV 3C protease or anti-HAV 3C protease antibodies. Arrows indicate the location
of the induced EMCVor HAV 3C protein. (C and D) Effect of proteasome inhibitor concentration on the accumulation of the EMCV 3C protease (panel C) and HAV
3C protease (panel D) in induced cells. pEGSH-E3C- or pEGSH-H3C-transfected cells were placed in medium containing ponasterone A and the indicated proteasome
inhibitor and incubated for 16 h at 37 °C in 5% CO2. The cells were harvested and lysed and 50 μg of lysate protein from each sample was analyzed by SDS-PAGE and
Western blotting using either anti-EMCV 3C protease or anti-HAV 3C protease antibodies. Arrows indicate the location of the induced EMCVor HAV 3C protein. The
inhibitor concentrations used were: MG132: lane 1, 0 μM; lane 2, 6.25 μM; lane 3, 12.5 μM; lane 4, 25 μM; lane 5, 50 μM. z-LLF-CHO: lane 1, 0 μM; lane 2,
12.5 μM; lane 3, 25 μM; lane 4, 50 μM; lane 5, 100 μM.MG115: lane 1, 0 μM; lane 2, 12.5 μM; lane 3, 25 μM; lane 4, 50 μM; lane 5, 100 μM.MG262: lane 1, 0 μM;
lane 2, 2.5 μM; lane 3, 5.0 μM; lane 4, 10 μM; lane 5, 20 μM. Clasto-lactacystin β-lactone (lactacystin): lane 1, 0 μM; lane 2, 2.5 μM; lane 3, 5.0 μM; lane 4, 10 μM;
lane 5, 20 μM.
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induction time courses under these conditions, with the induced
proteins becoming detectable by immunoblotting of whole cell
lysate preparations between 8 and 12 h post-induction and
maximum levels of the 3C proteases accumulating between 12
and 20 h post-induction (Figs. 1A and B). Levels of 3C protease
accumulating in induced cells were found to depend upon the
concentration of inhibitor included (Figs. 1C and D). The range
of inhibitor concentrations selected for these experiments was
based upon their published Ki or in vivo IC50 values, although it
should be noted that these values are likely to vary with cell
type. The results shown in Fig. 2 demonstrate the requirement
for both inducing conditions and a proteasome inhibitor to allow
expressed 3C protease detection.Fig. 2. Demonstration that both ponasterone A and proteasome inhibition are
required for expressed 3C protease detection. pEGSH-E3C- or pEGSH-H3C-
transfected cells were placed in medium containing no additives, ponasterone A
only, 25 μM MG132 only, or both ponasterone A and 25 μM MG132 and
incubated for 16 h at 37 °C in 5% CO2. The cells were harvested and lysed and
50 μg of lysate protein from each sample was analyzed by SDS-PAGE and
Western blotting using either anti-EMCV 3C protease or anti-HAV 3C protease
antibodies. Lanes containing purified EMCV or HAV 3C protease marker
proteins are indicated by ‘M’.To confirm directly that the accumulation of the 3C proteases
in the induced cells is the result of proteasome inhibition, cells
were incubated with the reversible inhibitor MG132 along with
ponasterone A to generate pools of stably expressed 3C
proteases, and the cells were incubated for additional time in
inducing media either containing or lacking MG132. As shown
in Fig. 3, the removal of the inhibitor resulted in a more rapid
reduction in the levels of both the EMCVand HAV 3C proteases
relative to the levels accumulating in cells still exposed to the
inhibitor. By 4 h after inhibitor removal, the accumulatedFig. 3. Comparison of expressed EMCV and HAV 3C protease levels after
proteasome inhibitor removal. pEGSH-E3C- or pEGSH-H3C-transfected cells
were placed in medium containing ponasterone A and 25 μM MG132 and
incubated for 16 h at 37 °C in 5% CO2. The inducing medium was replaced with
fresh inducing medium or inducing medium containing MG132, and the cells
were incubated at 37 °C in 5% CO2. The cells were harvested and lysed at the
indicated times following media change and 50 μg of lysate protein from each
sample was analyzed by SDS-PAGE and Western blotting using either anti-
EMCV 3C protease or anti-HAV 3C protease antibodies. (A) Western blotting
analysis of lysates prepared from EMCV 3C protease-expressing pEGSH-E3C-
transfected cells. (B) Western blotting analysis of lysates prepared from HAV 3C
protease-expressing pEGSH-H3C-transfected cells. Arrows indicate the location
of the EMCVor HAV 3C proteins.
Fig. 4. Detection of ubiquitin-3C protease conjugates in cells cultured under
inducing conditions. pEGSH-E3C- or pEGSH-H3C-transfected cells were
placed in medium containing either 25 μM MG132 (non-inducing conditions,
‘Unind’) or ponasterone A and 25 μM MG132 (inducing conditions, ‘Ind’) and
incubated for 16 h at 37 °C in 5% CO2. The cells were harvested and lysed and
225 μg aliquots of lysate protein were immunoprecipitated in the absence (−) or
presence (+) of the appropriate anti-3C protease antibodies (Ab). The
immunoprecipitated samples were then subjected to SDS-PAGE and Western
blotting using either anti-3C protease antibodies or anti-ubiquitin antibodies.
Lanes containing purified 3C protease marker proteins are indicated by ‘M’. The
locations of immunoprecipitated polyubiquitinated conjugates are indicated by
brackets. (A) Immunoprecipitation and Western blotting analysis of lysates
prepared from EMCV 3C protease-expressing pEGSH-E3C-transfected cells.
(B) Immunoprecipitation and Western blotting analysis of lysates prepared from
HAV 3C protease-expressing pEGSH-H3C-transfected cells.
Fig. 5. Demonstration that both ER-NIH3T3 and HeLa cells contain HAV 3C
protease-ubiquitinating activity. Reaction mixtures containing cytoplasmic
fraction preparations from ER-NIH3T3 and HeLa cells, along with methylated
ubiquitin (MeUb), an ATP-regenerating system, and purified HAV 3C protease
were incubated at 37 °C and aliquots were removed at the indicated times for
analysis by SDS-PAGE and Western blotting using anti-HAV 3C protease
antibodies.
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more. This is about the time previously shown to allow for
complete reversibility of MG132-dependent proteasome inhibi-
tion in cultured cells (Lee and Goldberg, 1996).
Inhibition of proteasome-mediated in vivo degradation of the
EMCV and HAV 3C proteases would be expected to be
accompanied by the synthesis and accumulation of polyubiqui-
tin-3C protease conjugates if the ubiquitin/26S proteasome
system is indeed responsible for the observed in vivo 3C
protease proteolysis. Candidate high molecular mass polyubi-
quitin conjugates were difficult to identify in the anti-3C
protease antibody-developed Western blots used to analyze the
induced whole cell lysates, possibly due to incompleteinhibition of proteasome activity combined with the presence
of cellular proteins cross-reacting with our antibodies. We
therefore performed double antibody recognition experiments
to detect conjugates synthesized in cells under inducing
conditions in the presence of MG132. We selected this inhibitor
because it routinely supported the highest level of 3C protease
protein accumulation (Fig. 1). Large-scale 16-h inductions of
3C protease expression were carried out and the whole cell
lysates were subjected to mock immunoprecipitation without
antibody or immunoprecipitation with either anti-EMCV 3C
protease or anti-HAV 3C protease antibodies, and the
precipitates were subjected to SDS-PAGE and Western blotting.
The blots were developed using primary anti-3C protease or
anti-ubiquitin antibodies. Immunoprecipitates from induced cell
lysates analyzed by anti-3C protease antibody-developed
Western blots were found to contain immunoprecipitated
EMCV or HAV 3C protease proteins (Figs. 4A and B,
respectively), as well as certain higher molecular mass proteins
which might represent polyubiquitin-3C protease conjugates.
These proteins are absent in the mock immunoprecipitated
sample lanes and in the lanes containing immunoprecipitated
lysate samples from uninduced cells. Blots developed using
anti-ubiquitin antibodies revealed the presence of a hetero-
geneous mixture of ubiquitin-containing proteins migrating
with apparent masses greater than the 3C proteases and
including a distinct ladder pattern, but only in sample lanes
containing induced cell lysates from the EMCV 3C protease-
expressing (Fig. 4A) or HAV 3C protease-expressing (Fig. 4B)
cell lines that were immunoprecipitated with the respective anti-
3C protease antibody. The migration pattern of the proteins in
these lanes is characteristic of polyubiquitinated conjugates
detected with anti-ubiquitin antibodies. These results confirm
that both the EMCV and HAV 3C proteases are polyubiquiti-
nated in vivo, undoubtedly as a prerequisite to 26S proteasome
recognition.
While we used a mouse cell line expression system to
evaluate the susceptibility of the EMCVand HAV 3C proteases
to in vivo ubiquitination, human and some primate cells are the
natural host for HAV (Bayalan, 1992). To confirm that human
cells possess HAV 3C protease-ubiquitinating activity, we
tested the ability of HeLa cell extracts to catalyze HAV 3C
protease ubiquitination. Methylated ubiquitin was used in these
assays because it cannot support the synthesis of polymeric
ubiquitin conjugates and facilitates the detection of ubiquitin–
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preparations from both ER-NIH3T3 and HeLa cells catalyze
HAV 3C protease ubiquitination.
One of the functions of the ubiquitin/26S proteasome system
is to eliminate misfolded proteins (Glickman and Ciechanover,
2002). To confirm that the 3C proteases expressed in our cell
lines are catalytically active, and therefore correctly folded, we
tested whole cell lysates prepared from cells cultured under
inducing conditions in the presence of a proteasome inhibitor
for their ability to catalyze the cleavage of in vitro synthesized
viral polyprotein substrates. As shown in Fig. 6A lysates
prepared from induced EMCV 3C protease-expressing cells
contain an activity that catalyzes the cleavage of the leader (L)
protein from the EMCV LVP0 polyprotein. The 2A protein was
found to be cleaved from the HAV VP2-VP3-VP1-2A
polyprotein by lysates prepared from induced HAV 3C
protease-expressing cells. EDTAwas included in these reaction
mixtures to inhibit the ATP-dependent degradation of the 3C
protease proteins. We have observed that purified EMCV 3C
protease much more efficiently catalyzes viral polyprotein
substrate cleavage than does purified HAV 3C protease. This
kinetic difference likely accounts for the longer incubation time
required to detect the in vivo expressed HAV 3C protease
cleavage products and the relatively small quantity of products
observed.
Effects of 3C protease expression on cell viability
We have hypothesized that the rapid destruction of the
EMCVand HAV 3C proteins might be necessary to prevent 3C
protease-mediated damage that is detrimental to virus replica-
tion, and we hoped to test this idea with our stably transfected
cell lines. Our attempts to evaluate the cytotoxic effects of theFig. 6. Evaluation of expressed EMCV and HAV 3C protease catalytic activity. pEG
either 50 μMMG132 (non-inducing conditions, ‘Unind’) or ponasterone A and 50 μM
The cells were harvested and lysed in a hypotonic buffer. 3C protease catalytic activ
protease (control reactions) and 35S-labeled viral polyprotein substrates were incubate
PAGE and phosphorimaging. (A) Analysis of the cleavage of the EMCV LVP0 poly
(B) Analysis of the cleavage of the HAV VP2-VP3-VP1-2A polyprotein by pEG
deliberately overexposed to facilitate visualization of the cleavage products. The loca
from HAV 3C protease-expressing cells cultured under inducing conditions is indic3C proteases post-induction were complicated, however, by the
need to prevent their simultaneous proteasome-dependent
degradation. All of the proteasome inhibitors used in this
study resulted in visible cytotoxic effects, in the form of general
morphological changes, a reduction in growth rate, and
eventually cell death. The extent of these effects was dependent
upon the particular inhibitor and inhibitor concentration used,
but for all of the inhibitors the effects typically became
noticeable after about 12 to 16 h of incubation and increased as
a function of time thereafter. These effects are to be expected,
because it is known that long-term exposure of cells to agents
that compromise proteasome function has detrimental effects on
a number of cellular processes and can trigger apoptotic
pathways (Wójcik, 2002). We carried out extensive testing of
several proteasome inhibitors over a wide range of concentra-
tions to evaluate the extent to which they cause obvious
cytotoxic effects during a 24-h exposure period while still
enabling the accumulation of a detectable level of the 3C
proteins under inducing conditions. We observed during the
course of these tests that relatively low concentrations of the
highly specific proteasome inhibitor lactacystin minimized
inhibitor-induced cytotoxicity. The induction of 3C protease
expression was therefore performed in the presence of 10 μM
lactacystin in order to assay 3C protease-dependent cytotoxicity
above that caused by the presence of a proteasome inhibitor.
We performed a systematic evaluation of the effect of the
EMCV and HAV 3C proteases on cell viability under both
inducing and non-inducing conditions in the presence or
absence of lactacystin. To control for non-protease specific
effects, we performed the same analysis on untransfected ER-
NIH3T3 cells as well as ER-NIH3T3 cells stably transfected
with pEGSH-Luc, a control plasmid that allows for inducible
expression of firefly luciferase protein, which is detectable withSH-E3C- or pEGSH-H3C-transfected cells were placed in medium containing
MG132 (inducing conditions, ‘Ind’) and incubated for 16 h at 37 °C in 5% CO2.
ity reaction mixtures containing either these lysate preparations or purified 3C
d at 30 °C and aliquots were removed at the indicated times for analysis by SDS-
protein by pEGSH-E3C-transfected cell lysates or purified EMCV 3C protease.
SH-H3C-transfected cell lysates or purified HAV 3C protease. The gel was
tion of the HAV 2A cleavage product from the reaction mixture containing lysate
ated by ‘*’.
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absence of a proteasome inhibitor (data not shown).
Our observations over a 24-h incubation period revealed that
the ER-NIH3T3 cells are detrimentally affected by lactacystin,
regardless of whether they express the 3C proteases, luciferase,
or neither. These effects became noticeable by approximately
12 h, but they were most severe in cells expressing the HAV 3C
protease (transfected with pEGSH-H3C). By 16 h it was clearFig. 7. Effect of EMCV and HAV 3C protease expression on cell viability. Equal
pEGSH-E3C-transfected (ER-NIH3T3/pEGSH-E3C), or pEGSH-H3C-transfected (E
24 h as described in Materials and methods. The cells were then placed in medium l
lactone (lactacystin), or in medium containing ponasterone A (induced), with or with
images of cells after 16-h incubation. B and C. Percent of living cells remaining after
(panel B) or with lactacystin (panel C). The cells were harvested, stained with trypan b
cultured under inducing conditions is calculated relative to the number of cells rem
deviations in the data obtained from three experiments for each cell line. (For data
except ER-NIH3T3/pEGSH-H3C cells cultured in media containing lactacystin, forthat for cells incubated in media containing lactacystin the
presence of the HAV 3C protease affected cell viability when
compared to the same cells under non-inducing conditions (Fig.
7A). These differences were not observed in cells expressing the
EMCV 3C protease (transfected with pEGSH-E3C) or with
either control cell line. No differences were observed with any
of the cell lines cultured under non-inducing vs. inducing
conditions in the absence of the proteasome inhibitor (Fig. 7A).numbers of ER-NIH3T3, pEGSH-Luc-transfected (ER-NIH3T3/pEGSH-Luc),
R-NIH3T3/pEGSH-H3C) cells were seeded into 12-well plates and cultured for
acking ponasterone A (uninduced), with or without 10 μM clasto-lactacystin β-
out lactacystin. The cells were incubated at 37 °C in 5% CO2. A. Representative
20-h incubation in non-inducing (−) or inducing (+) medium without lactacystin
lue, and counted. The percent of living cells remaining in each population of cells
aining after incubation in non-inducing media. The error bars show standard
comparing uninduced and induced cell populations P=0.1365 to 0.7537 for all
which P<0.001.)
Fig. 8. Cytoplasmic vs. nuclear distribution of the expressed EMCV 3C and
HAV 3C proteases. pEGSH-E3C- or pEGSH-H3C-transfected cells were placed
in medium containing ponasterone A and 25 μMMG132 and incubated for 16 h
at 37 °C in 5% CO2. The cells were harvested and cytoplasmic (C) and nuclear
(N) extracts prepared as described in Materials and methods. Samples from
EMCV 3C protease-expressing cells (panel A) and HAV 3C protease-expressing
cells (panel B) containing 20 μg of protein were analyzed by SDS-PAGE and
Western blotting with antibodies against EMCV 3C protease, HAV 3C protease,
glyceraldehyde 3-phosphate dehydrogenase (G3PDH; cytoplasmic marker
protein), or poly-ADP-ribose-polymerase (PARP; nuclear marker protein).
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transfected cell lines. Our interpretation of these observations
was confirmed by the quantification of the number of viable
cells remaining in each culture after 20 h. As shown in Fig. 7B,
in the absence of lactacystin there were no significant
differences in the percentage of living control, EMCV 3C
protease-expressing, or HAV 3C protease-expressing cells
remaining in the cultures subjected to inducing conditions
relative to cells incubated in the non-inducing medium. In the
presence of the proteasome inhibitor, however, a significantly
smaller fraction of the HAV 3C protease-expressing cells
subjected to inducing conditions retained viability (Fig. 7C).
These results indicate that the expression of the HAV 3C
protease, under conditions of at least partial proteasome
inhibition, negatively impacts cell viability. Our data indicate
that EMCV 3C protease expression under similar conditions
does not contribute to cytotoxicity, but effects on cell growth
mediated by this protein could easily be masked by those
resulting from incubation with the proteasome inhibitor. It does
not appear that the inducing conditions alone can account for
any additional level of cytotoxicity beyond that due to the
inhibitor, because neither the untransfected cells nor the
luciferase-expressing cells were affected by incubation with
ponasterone A in the presence or absence of lactacystin.
Subcellular localization of the expressed 3C proteases
The poliovirus, human rhinovirus, and EMCV 3C proteases
have been shown to be trafficked to the nuclear compartment in
infected cells (Aminev et al., 2003, 2004; Sharma et al., 2004;
Weidman et al., 2003). The 3D RNA polymerase proteins of
several picornaviruses contain a nuclear localization signal
(NLS) (Dingwall and Laskey, 1991), which appears to be
responsible for the translocation of the 3D protein and 3D-
containing precursors across the nuclear membrane (Aminev et
al., 2003; Diamond and Kirkegaard, 1994; Sharma et al., 2004).
Subsequent processing within the nucleus apparently releases
free 3C protease. The cleavage of transcription factors in the
nucleus is emerging as an important function of at least some
picornavirus 3C proteases, making the issue of nuclear
trafficking important. We therefore examined whether the
mature EMCV and HAV 3C proteases localize to the nucleus
in the absence of other viral proteins.
Soluble cytoplasmic and nuclear extracts were prepared
from cell lines expressing the EMCV and HAV 3C proteases
in the presence of MG132. Analysis by SDS-PAGE and
Western blotting of the cytoplasmic and nuclear fractions
prepared from cells incubated under inducing conditions for
16 h revealed the presence of the EMCV 3C protease in both
fractions, with the majority associated with the nuclear
fraction (Fig. 8A). The HAV 3C protease, on the other hand,
was found only in the cytoplasmic fraction (Fig. 8B). The
partitioning of the nuclear and cytoplasmic proteins in these
experiments was confirmed using glyceraldehyde 3-phosphate
dehydrogenase (G3PDH) and poly-ADP-ribose-polymerase
(PARP) as cytoplasmic and nuclear marker proteins, respec-
tively (Dastoor and Dreyer, 2001; Hara et al., 2005; Minascheket al., 1992). The unequal distribution of these proteins between
the subcellular fractions indicates that the general structural
integrity of the nuclear membrane has not been compromised by
the inducing conditions or presence of the proteasome inhibitor.
While G3PDH lacks an NLS and is typically localized primarily
in the cytoplasm, it has recently been found that a significant
fraction of this protein is translocated into the nuclear
compartment under conditions of stress-induced apoptosis
(Dastoor and Dreyer, 2001; Hara et al., 2005; Kim et al.,
2006). We found that neither our inducing conditions nor
proteasome exposure altered the partitioning of G3PDH in our
experiments (data not shown).
Our results show that a substantial fraction of the mature
EMCV 3C protease is preferentially localized to the nucleus,
while the HAV 3C protease is not, at least under conditions of
reduced proteasome activity. Because the nuclear compartment
is known to contain ubiquitin-conjugating pathway enzymes
and the proteasome complex (for review see von Mikecz, 2006),
an interesting question is whether 3C proteins localized to the
nucleus are degraded by the nuclear ubiquitin/26S proteasome
system. To answer this question we performed double antibody
recognition experiments with nuclear fractions prepared from
EMCV 3C protease-expressing cells cultured under non-
inducing or inducing conditions for 16 h in the presence of
MG132. Samples were subjected to immunoprecipitation with
anti-EMCV 3C protease antibodies, followed by SDS-PAGE
and Western blotting with either anti-3C protease or anti-
ubiquitin antibodies. As shown in Fig. 9, anti-3C protease
antibody-precipitated proteins included little or none of the high
molecular mass polyubiquitinated EMCV 3C protease con-
jugates detected in induced whole cell lysates. (Compare the
induced cell nuclear fraction protein sample immunoprecipi-
tated with anti-3C protease antibodies and blotted with anti-
ubiquitin antibodies in Fig. 9 with the similarly immunopreci-
pitated and blotted induced whole cell lysate sample in Fig. 4A).
Consistent with this result, we found that the nuclear extract
preparations do not support the ubiquitination of purified 3C
proteases in the presence of methylated ubiquitin and an ATP-
regenerating system (data not shown). These results suggest that
Fig. 9. Evaluation of EMCV 3C protease-expressing cell nuclear fraction for the
presence of ubiquitin-EMCV 3C protease conjugates. pEGSH-E3C-transfected
cells were placed in medium containing either 25 μM MG132 (non-inducing
conditions, ‘Unind’) or ponasterone A and 25 μMMG132 (inducing conditions,
‘Ind’) and incubated for 16 h at 37 °C in 5% CO2. The cells were harvested and
nuclear fractions prepared as described in Materials and methods. One hundred
μg aliquots of nuclear fraction protein were immunoprecipitated in the absence
(−) or presence (+) of anti-EMCV 3C protease antibodies. The immunopreci-
pitated samples were then subjected to SDS-PAGE and Western blotting using
either anti-EMCV3C protease antibodies or anti-ubiquitin antibodies. The lane
containing purified EMCV 3C protease marker proteins is indicated by ‘M’.
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incorporated in vivo into conjugates with ubiquitin.
Discussion
The mature EMCV 3C protease has been shown to be rapidly
turned over in virus-infected cells and evidence consistent with
the rapid proteolysis of the HAV 3C protease in infected cells
has been reported (Jia et al., 1991; Lawson et al., 1989). We
have demonstrated that both of these 3C proteases, as well as
certain 3C protease-containing polyprotein precursors, are
substrates for rapid degradation by the ubiquitin/26S protea-
some system in vitro (Lawson et al., 1994, 1999; Losick et al.,
2003). Studies using purified, reconstituted ubiquitin-conjugat-
ing reaction systems have revealed that both the EMCV and
HAV 3C proteases are recognized by three different ubiquitin-
conjugating pathways (Lawson et al., 1999, 2001; Schlax and
Lawson, unpublished), suggesting a strong evolutionary
pressure for the degradation of these proteins. Evidence directly
demonstrating the ubiquitin-mediated in vivo destruction of the
EMCVand HAV 3C proteases has been lacking, however. This
is an important point, because it is possible that one or more
other proteases, and not the 26S proteasome, are responsible for
3C protease degradation in intact cells.
To answer the question of whether the ubiquitin/26S
proteasome system is responsible for EMCV and HAV 3C
protease degradation in cells and to attempt to answer questions
regarding 3C protease cytotoxicity we prepared mouse NIH3T3
cell lines stably transfected with genes coding for the mature 3C
proteases under the control of a promoter activated by a
synthetic heterodimeric ecdysone/retinoid-X-receptor protein.We found that our ability to detect the expression of both 3C
proteases in the cells required the presence of both the inducing
agent and one of several different cell-permeable inhibitors of
proteasome proteolytic activity, demonstrating that the 26S
proteasome at least contributes to the in vivo degradation of
both proteins. Of the inhibitor compounds tested the reversible
inhibitor MG132 proved to consistently allow the highest level
of 3C protease expression in our cells. Another inhibitor,
lactacystin, required media concentrations ten times the
reported IC50 value of 1 μM for detectable levels of both 3C
proteases to accumulate under inducing conditions, even though
this compound is known to be the most specifically directed of
our inhibitor set against proteasome proteolytic activity (Craiu
et al., 1997; Dick et al., 1997; Fenteany and Schreiber, 1998).
Even in the presence of 20 μM lactacystin the expressed protein
levels remained well below those achieved in the presence of
MG132, which was typically provided at a concentration five
times the published IC50 value of 5 μM. The limited
effectiveness of lactacystin in supporting 3C protease accumu-
lation under the inducing conditions may be a function of the
cell line we used for the stable transfections, but it could also
mean that other cellular proteases contribute to the in vivo
destruction of the 3C proteins. Even if this is the case, additional
evidence confirming the significant, if not exclusive, involve-
ment of the ubiquitin/26S proteasome system in the in vivo
degradation of both the EMCV and HAV 3C proteases was
obtained from experiments which showed that both of the
expressed 3C proteases are incorporated in vivo into conjugates
with polyubiquitin.
We have hypothesized that the degradation of the mature
EMCV and HAV 3C proteases may be a necessary part of their
respective viral replication cycle. It is conceivable, for
example, that the accumulation of these 3C proteases in
infected cells could interfere with efficient virus replication by
cleaving one or more host proteins required for host cell
viability. In conjunction with the experiments described here,
we attempted to determine whether proteasome inhibitors result
in 3C protease accumulation in virus-infected cells and whether
this accumulation interferes with viral replication efficiency.
We discovered, however, that infections could not be
established in proteasome inhibitor-treated cells, rendering
these studies impossible to perform. We therefore performed
experiments designed to determine whether either the EMCVor
HAV 3C protease, expressed in our stably transfected cell lines,
is on its own toxic to cells. Our efforts were hampered by the
onset of cytotoxic effects resulting from the necessary inclusion
of a proteasome inhibitor in the media during induction of 3C
protease gene expression. Proteasome inhibitors have been
shown to induce apoptosis in dividing cells (Wójcik, 2002), so
the effects of the inhibitors on our cell lines are not surprising.
In spite of this complication we obtained evidence from
observations and cell counting that the induction of HAV 3C
protease synthesis in the presence of a proteasome inhibitor
resulted in a greater fraction of the cells dying within a 20-h
period than in the presence of the inhibitor without induced 3C
protease expression. This suggests that the HAV 3C protease
has a detrimental impact on cell viability, at least under
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reduced. We attempted to isolate cell lines expressing the
mutated HAV 3C(C172A) protein to determine whether the
HAV 3C protease-caused cytotoxicity requires the catalytically
active protein. While we were able to isolate a large number of
G418- and hygromycin-resistant colonies following transfec-
tion with pEGSH carrying the HAV 3C(C172A) gene, we
could not detect HAV 3C(C172A) protein expression in any of
the transfected cell lines. We have found in our laboratory that
point mutations in the catalytic region of the HAV 3C protease
can alter folding stability and solubility, so it is possible that an
intact in vivo expressed HAV 3C(C172A) protein is not able to
accumulate.
We observed that EMCV 3C protease expression resulted in
no obvious cytotoxicity beyond that caused by the proteasome
inhibitor. This does not prove that the EMCV 3C protein does
not interfere with processes required for cell viability, because
damaging effects caused by the 3C protease accumulation in
induced cells may be masked by the effects of the lactacystin
used in these experiments. It is important to note that in vivo
expression of the EMCV 3C protease has been previously
achieved in cells stably transfected with the cloned gene under
the control of the mouse metallothionine (mMT-I) promoter
(Lawson et al., 1989), but in that case a polyprotein chimera
containing the carboxyl terminal portion of the 3A protein, the
entire 3B and 3C proteins, and the N-terminal region of the 3D
RNA polymerase (3A'BCD' polyprotein) was the primary
product. This earlier expression system also had the undesirable
requirement for a preliminary, long-term global inhibition of
translation and exposure to Zn2+ followed by the global
inhibition of transcription. As in this study, the levels of
accumulated induced expression products were low, and it was
difficult to detect the mature 3C protease that resulted from the
processing of the 3A'BCD' polyprotein. The expression of this
version of the EMCV 3C protein also did not result in obvious
cytotoxic effects to the cells, but the expressed products
disappeared rapidly after the initial induction.
Because the 3C proteases of several picornaviruses,
including EMCV, have been shown to be translocated into
the nucleus of infected cells (Aminev et al., 2003, 2004;
Sharma et al., 2004; Weidman et al., 2003), we examined the
cytoplasmic vs. nuclear distribution of the EMCVand HAV 3C
proteases in our expressing cell lines. We found that the EMCV
3C and HAV 3C proteases were unequally and differentially
partitioned between cytoplasmic and nuclear fractions prepared
from induced cells. Specifically, we detected little or no
expressed HAV 3C protease in the nuclear fraction, suggesting
that this protein is not translocated into, nor is tightly
associated with, the nucleus. However, for the EMCV 3C
protease, the 3C protein was isolated in both the nuclear and, to
a lesser extent, cytoplasmic protein fractions. Although the
biochemical sub-cellular fractionation procedure we used is
designed to recover soluble nuclear extracts from whole cells,
it is formally possible that the EMCV 3C protease we detected
in the nuclear fraction is actually tightly associated in vivo with
the nuclear membrane rather than translocated into the nuclear
compartment. This is unlikely, however, because such a tightassociation with the nuclear membrane would be expected to
sequester a significant fraction of the expressed 3C protease
from degradation by the ubiquitin/26S proteasome system. The
absolute requirement for proteasome inhibition to detect any
3C protease protein in the cells under inducing conditions
argues that this does not occur.
Additionally, an examination of the EMCV 3C protease pool
found in the nuclear fraction revealed an absence of
polyubiquitinated conjugates, suggesting that the portion of
the EMCV 3C protein which is localized to the nucleus is
rendered unavailable to the ubiquitin-conjugating pathways that
recognize this protein as a substrate. Consistent with this result,
previous investigations in our laboratory have shown that the
pathways which target the EMCV and HAV 3C proteases for
ubiquitination are located in the cytoplasm and include
cytoplasmic ubiquitin-conjugating pathway enzymes (Lawson
et al., 1994, 1999, 2001; Losick et al., 2003; Schlax and
Lawson, unpublished results). These results, along with the fact
that proteasome inhibition is required for the EMCV 3C
protease to accumulate in our expressing cell lines under
inducing conditions, are consistent with a scenario in which the
mature EMCV 3C protein can move in both directions between
the cytoplasm and nucleus but is subject to proteolysis only by
the cytoplasmic ubiquitin/26S proteasome system.
Aminev et al. have shown that the EMCV 3C protease
enters the nucleus of virus-infected cells as part of the viral
3BCD polyprotein precursor and that this requires a nuclear
localization signal in the 3D RNA polymerase segment of the
chimera (Aminev et al., 2003). This is the likely route by which
most of the mature EMCV 3C protease is relocated into the
nucleus in virus-infected cells. The fusion of the 3D RNA
polymerase to the 3C protease inhibits 3C protease-targeted
ubiquitination and renders the polyprotein relatively stable in
vitro (Lawson et al., 1994), so the majority of the 3C protein is
likely to be found in 3D RNA polymerase-containing
precursors. While our data reveal that a mechanism for the
translocation of mature EMCV 3C protease into the nucleus
may exist, such a mechanism may not function if the
proteasome population is fully active. In addition, picornavirus
infection can result in changes in the nuclear transport
machinery, which, as was shown with polio- and rhinovirus,
is accompanied by alterations in the nuclear pore complex
(Gustin and Sarnow, 2001, 2002). The nuclear translocation of
picornaviral proteins in the absence of infection may therefore
not accurately mimic events that occur during infection.
The results reported here provide the first direct evidence for
the in vivo degradation of picornavirus proteins by the
ubiquitin/26S proteasome system and forge an important link
with studies characterizing in vitro ubiquitination and degrada-
tion of the EMCV and HAV 3C proteases. Given the crucial
function served by picornavirus processing proteases in
generating mature viral proteins and altering fundamental
cellular processes to provide an environment necessary for
virus replication, understanding the factors that influence 3C
protease activity is imperative. Clearly, the degradation of the
mature EMCV and HAV 3C proteases must serve to reduce the
concentration of these proteins during infection, probably in a
359P.E. Schlax et al. / Virology 360 (2007) 350–363compartment-specific manner. Our finding that the mature
EMCV 3C protease is sequestered from ubiquitination by
nuclear localization suggests that mature EMCV 3C protease
generated in the nucleus by the processing of viral polyprotein
precursors in infected cells is probably also protected from rapid
degradation. This would allow the protein to accumulate in the
nucleus and raises the question of whether the EMCV 3C
protease catalyzes the cleavage of certain nuclear proteins, as
has been reported for the 3C proteases of some other
picornaviruses (Amineva et al., 2004; Falk et al., 1990;
Weidman et al., 2003). The discovery that HAV 3C protease
expression can reduce cell viability represents the first step in
developing an explanation for why some 3C proteases have
evolved into substrates for ubiquitin-mediated proteolysis.
Materials and methods
Chemicals, reagents, and cells
Protease inhibitor cocktail, hygromycin B, Dulbecco's
modified Eagle's medium with 4500 mg/L glucose (DMEM),
newborn calf serum, L-glutamine, penicillin–streptomycin, goat
anti-rabbit and anti-mouse IgG alkaline phosphatase conjugates,
and Staphylococus aureaus protein A Sepharose were from
Sigma (St. Louis, MO). Mouse glyceraldehyde-3-phosphate
dehydrogenase (G3PDH) monoclonal antibody was obtained
from Chemicon International (Temecula, CA). Bovine poly-
ADP-ribose-polymerase (PARP) monoclonal antibody was
from eBioscience (San Diego, CA). Geneticin (G418 sulfate)
was from Gibco Invitrogen Corporation (Carlsbad, CA). BCIP/
NBT and Lumi-Phos WB phosphatase substrates were from
Kirkegaard and Perry Laboratories (Gaithersburg, MD) and
Lumigen, Inc. (Southfield, MI), respectively. ECL Plus and
ECF detection systems and L-[35S]-methionine were from
Amersham Biosciences (Piscataway, NJ). Pfu DNA polymer-
ase, ponasterone A, anti-luciferase antibodies, ER-NIH3T3 cell
line, pEGSH, and pEGSH-Luc plasmids, and the accompanying
license for the Complete Control inducible mammalian
expression system were from Stratagene (La Jolla, CA). All
restriction endonucleases were from New England Biolabs
(Beverly, MA). NE-PER nuclear and cytoplasmic extraction
reagents were from Pierce Biotechnology (Rockford, IL).
Ubiquitin aldehyde, clasto-lactacystin β-lactone (lactacystin),
z-Leu-Leu-Phe-CHO (z-LLF-CHO), z-Leu-Leu-Leu-CHO
(MG132), z-Leu-Leu-Nva-CHO (MG115), z-Leu-Leu-Leu-B
(OH)2 (MG262), and HeLa cell S100 preparation were from
Boston Biochem (Cambridge, MA). X-OMAT X-ray film was
from Eastman Kodak Corporation (Rochester, NY). Immobi-
lon-P 0.45 μM pore size polyvinylidene difluoride (PVDF)
membrane was from Millipore Corporation (Billerica, MA). T7
in vitro transcription and rabbit reticulocyte in vitro translation
systems were from Promega (Madison, WI). Polyclonal anti-
EMCV 3C protease and anti-HAV 3C protease antibodies were
raised in rabbits, using the 3C proteins purified as previously
described from expressing E. coli cells as antigens, and were
purified from sera by 3C protease affinity chromatography
(Lawson et al., 1994). Methylated ubiquitin was prepared aspreviously described (Hershko and Heller, 1985). Anti-
ubiquitin antibodies were the generous gift of Cecile Pickart.
pE5LVP0 was kindly provided by Ann Palmenberg, and
pEXT7-HM/HAS-VP2-2A/(E/S) was kindly provided by
Christian Probst and Verna Gaus-Müller.
Plasmid constructions
pEGSH-E3C, carrying the EMCV 3C protease gene was
constructed by PCR amplification of the EMCV 3C protease-
encoding sequence from pE3C (Gladding et al., 1997). Coding
strand (5′-TTTTGAATTCATGGGACCAAACCCTGTGATGG-
3′) and non-coding strand (5′-AAAAGGATCCTTACT-
GTGGCTCAAAGGCATTC-3′) PCR primers containing EcoRI
and BamHI restriction endonuclease sites, respectively, were used
to amplify and directionally subclone the 3C gene into the multiple
cloning site of the ponasterone A-inducible mammalian transcrip-
tion cassette of the pEGSH plasmid. This plasmid was then used as
a template for “QuickChange” complementary primer pair directed
mutagenesis (Stratagene; La Jolla, CA) to insert a strong in-frame
translation start codon (Kozak, 1987), embedded in an NcoI site,
immediately upstream of the EMCV3C gene, using the coding and
non-coding strand primers 5′-CAGCAGAAGAGCAATTGC-
CATGGGACCAAACCCTGTGATG-3′ and 5′-CATCA-
CAGGGTTTGGTCCCATGGCAATTGCTCTTCTGCTG-3′,
respectively. To construct pEGSH-H3C, carrying the HAV 3C
protease gene, coding strand (5′-AAAAGAATTCCCATGGAAT-
CTCAGTCAACTTTGGAAATAGC-3′) and non-coding strand
(5′-AAAAGGATCCATCTGACTTTCAATTTTCTTATCAA-
TATTTTGGAAC-3′) PCR primers were used to amplify the HAV
3C protease-encoding sequence from pHAV3C (Gladding et al.,
1997), and this was subcloned into the pEGSH plasmid as
described above. The final insert sequences were confirmed via
dideoxy sequence analysis (MWG Biotech; High Point, NC).
Mammalian cell propagation, transfection and colony
screening
Unless stated otherwise, cells were grown as monolayer
culture in DMEM containing 10% bovine calf serum, 100 units/
ml penicillin, 100 μg/ml streptomycin, and 2 mM glutamine
(standard medium) at 37 °C in 5% CO2, with either 200 μg/ml
G418 (for the ER-NIH3T3 cell line) or 200 μg/ml G418 and
100 μg/ml hygromycin B (for the ER-NIH3T3/pEGSH-E3C,
ER-NIH3T3/pEGSH-H3C, and ER-NIH3T3/pEGSH-Luc cell
lines). Stable double transfectants were prepared using an
Electro Cell Manipulator 600 electroporation device (BTX Inc.;
San Diego, CA). Briefly, 10×106 ER-NIH3T3 mouse embryo-
nic fibroblast (MEF) cells were transfected with 50 μg of AsnI-
linearized pEGSH-E3C, pEGSH-H3C, or pEGSH-Luc plasmid
DNA in a total volume of 0.5 ml. The transfected cells were
added to 20 ml standard DMEM and grown in 150 mm tissue
culture-treated plates for 24 h before challenging with 200 μg/ml
hygromycin and 250 μg/ml G418. Following 14 to 20 days of
hygromycin/G418 selection, the resulting individual colonies
were picked, trypsinized and disaggregated, and expanded in 96
well plates for subsequent propagation and selection.
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A-inducible 3C protease protein or luciferase expression by
SDS-PAGE and Western blotting analysis of lysates (see below)
prepared from cells incubated for 16 or 20 h in standard media
containing 10 μM ponasterone A and 25 μM MG132. To
simplify the process of identifying the 3C protease-expressing
colonies, we developed a combinatorial screening method in
which cell lysates from groups of five individually induced
colonies were pooled and analyzed. Colonies associated with
lysate pools demonstrating detectable 3C protease expression
were subsequently screened individually. About 10% of all
screened colonies had detectable levels of 3C protease
expression, and those having the highest levels of expression
were used in subsequent experiments.
Detection of 3C protease expression and evaluation of
proteasome inhibitor effects
For routine detection of 3C protease expression and the
evaluation of proteasome inhibitor effects on 3C protease
accumulation, cells were cultured in 24- or 12-well plates to
70 to 80% confluency in standard medium containing 200 μg/
ml G418 and 100 μg/ml hygromycin B. This medium was
then replaced with standard medium containing either 10 μM
ponasterone A, added from a stock ethanol solution (inducing
medium), or standard medium containing an equivalent
volume of ethanol (non-inducing medium). For experiments
requiring the inclusion of a proteasome inhibitor, the inhibitor
was dissolved in dimethyl sulfoxide (DMSO) and included in
the media at the indicated concentration(s). When appropriate,
control media containing equivalent volumes of DMSO alone
were used. The cells were then incubated at 37 °C in 5% CO2.
Inductions were terminated at the indicated times by removing
the media, washing the cells with phosphate-buffered saline
(PBS), and then incubating the cells on ice for 20 min with
RIPA lysate buffer (50 mM Tris–HCl, pH 7.4, 150 mM NaCl,
1% Triton x-100, 1% sodium deoxycholate, and 0.1% sodium
dodecyl sulfate). Lysate viscosity was reduced via the
mechanical shearing of chromosomal DNA by multiple passes
through a 200 μl micropipetor tip. The RIPA lysates were then
cleared via centrifugation for 5 min at ∼15,000×g (4 °C),
transferred to clean tubes, and assayed for protein concentra-
tion using the Bradford reagent. For experiments designed to
examine the effects of proteasome inhibitor removal on 3C
protease stability, cells were incubated for 16 h in inducing
medium containing 25 μM MG132, after which the medium
was removed, and the cells were washed with PBS and then
provided with fresh inducing medium containing 10 μM
ponasterone A or inducing medium containing 10 μM
ponasterone A and 25 μM MG132. The cells were then
incubated for the indicated additional times at 37 °C in 5%
CO2 and were processed and lysed as described above. Lysate
samples containing 50 μg of protein were subjected to SDS-
PAGE and Western blotting analysis using the appropriate
primary anti-3C protease antibodies and alkaline phosphatase-
conjugated secondary antibodies. Purified 3C proteases were
included as standards in all SDS-PAGE and Western blotanalyses. The blots were developed using either Lumi-phos
WB and X-ray film exposure or ECF alkaline phosphatase
reagent and scanning with a Fuji FLA-5000 imaging system
(473 nm excitation laser and 575 nm emission filter). For the
detection of luciferase expression by control pEGSH-Luc-
transfected cells, the above procedure was used, except that
the inducing medium did not include a proteasome inhibitor
and Western blotting was carried out using primary anti-
luciferase antibodies.
Ubiquitin-3C protease conjugate detection
For experiments designed to detect polyubiquitin-3C
protease conjugates generated in the cells under inducing
conditions, the pEGSH-E3C- or pEGSH-H3C-transfected cells
were cultured in 100 mm dishes to 70 to 80% confluency in
standard medium containing 200 μg/ml G418 and 100 μg/ml
hygromycin B. This medium was then replaced with either
inducing medium containing 10 μM ponasterone A and 25 μM
MG132 or non-inducing medium containing 25 μM MG132
and incubated for 16 h at 37 °C in 5% CO2. The cells were
washed with PBS and harvested by scraping with a rubber
policeman into 1 ml PBS/plate. The cells were pelleted by
centrifugation for 2 min at 1300×g, re-suspended in 10 volumes
of fresh PBS, and pelleted again. The cells were re-suspended in
approximately 10 volumes of RIPA buffer and the total protein
concentration was determined using the Bradford reagent.
225 μg aliquots of whole cell total protein were mock
immunoprecipitated, without antibody, or immunoprecipitated
with anti-3C protease antibody as previously described (Law-
son et al., 1994). The precipitates were subjected to SDS-PAGE
and Western blotting using anti-3C protease or anti-ubiquitin
primary antibodies and alkaline phosphatase-conjugated sec-
ondary antibodies. The blots were developed using the ECF
alkaline phosphatase reagent as described above.
In vitro ubiquitination assays
ER-NIH3T3 post-nuclear supernatant preparations were
prepared from cultures of 50×106 cells grown in 100 mm
dishes, which were trypsinized, pelleted by centrifugation for
5 min at 1300×g, washed twice with 6 ml cold PBS, and
resuspended to a total volume of 3 ml in 50 mM Tris–HCl,
pH 7.6, 50 mM NaCl, and 2 mM DTT. The cells were frozen
at −80 °C, thawed, and passed 15 times through a 0.22 gauge
needle to complete the lysis. This material was centrifuged for
5 min at 2000×g and the resulting post nuclear supernatant
removed. The protein concentration was determined using the
Bradford reagent. In vitro ubiquitination assays with the ER-
NIH3T3 or HeLa cytoplasmic preparations and purified HAV
3C protease were performed essentially as previously described
(Lawson et al., 1999). Briefly, 3 to 5 mg/ml of cytoplasmic
protein preparations were incubated for 10 min at room
temperature with a buffered solution containing an ATP-
regenerating system and 1.5 μM ubiquitin aldehyde. Five μM
HAV3C protease protein and 100 μMmethylated ubiquitin were
then added and the mixtures incubated at 37 °C. Aliquots were
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PAGE and Western blotting as described above.
Evaluation of expressed 3C protease catalytic activity
For experiments designed to detect in vivo expressed 3C
protease catalytic activity, the pEGSH-E3C- or pEGSH-H3C-
transfected cells were each cultured in 100 mm dishes to 70 to
80% confluency in standard medium containing 200 μg/ml
G418 and 100 μg/ml hygromycin B. This medium was then
replaced with either inducing medium containing 10 μM
ponasterone A and 50 μM MG132 or non-inducing medium
containing 50 μMMG132 and incubated for 16 h at 37 °C in 5%
CO2. The cells were washed with PBS and harvested by
scraping with a rubber policeman into 1 ml PBS/plate. The cells
were pelleted by centrifugation for 2 min at 1300×g, re-
suspended in 1 volume of cold 10 mM HEPES, pH 7.5, 10 mM
KCl, 1.5 mM MgCl2, and 2 mM DTT. The suspension was
subjected to three freeze–thaw cycles, and the insoluble
material was removed by centrifugation for 2 min at 1300×g.
The protein concentrations of the final whole cell lysates were
determined using the Bradford reagent.
35S-labeled viral polyprotein substrates were prepared by in
vitro transcription and translation based upon the previously
described procedures (Oberst et al., 1993). pE5LVP0 (Parks et
al., 1986) was linearized by digestion with XbaI and pEXT7-
HM/HAS-VP2-2A/(E/S) (Probst et al., 1998) was linearized by
digestion with XhoI. Both plasmids were transcribed using T7
RNA polymerase. The RNA was purified and translated in
reaction mixtures containing rabbit reticulocyte lysate and
L-[35S]-methionine. 3C protease activity assay reaction mix-
tures contained 2.5 mg/ml whole cell lysate protein in 20 mM
HEPES, pH 7.5, 2 mM EDTA, 1 mM DTT, and 40% by volume
of the appropriate polyprotein in vitro translation reaction
mixture. Positive control reactions contained 5 μM purified
EMCV or HAV 3C protease in place of the cell lysate protein.
The reaction mixtures were incubated at 30 °C for the indicated
times, and aliquots were removed for analysis by SDS-PAGE
and phosphorimaging.
Evaluation of 3C protease expression effects on cell viability
The effects of EMCVand HAV 3C protease gene expression
on cell viability were evaluated by incubating the pEGSH-E3C-
and pEGSH-H3C-transfected cells under non-inducing and
inducing conditions in the absence or presence of proteasome
inhibitor, with the ER-NIH3T3 and pEGSH-Luc-transfected
cells as controls. 56,000 cells/well were seeded into 12-well
plates and incubated for 24 h at 37 °C in 5% CO2 in standard
medium containing 200 μg/ml G418 and 100 μg/ml hygro-
mycin B. This medium was then replaced with one of four
media: non-inducing medium, non-inducing medium contain-
ing 10 μM lactacystin, inducing medium containing 10 μM
ponasterone A, or inducing medium containing both 10 μM
ponasterone A and 10 μM lactacystin. The cells were then
incubated at 37 °C in 5% CO2, and beginning 8 h later the cells
were observed and imaged at 4-h intervals using a Moticam1000 CCD camera mounted on an Olympus model CK40-F100
phase contrast microscope. After 20 h the cells were washed
with PBS, trypsinized, and suspended in PBS containing 0.2%
(w/v) trypan blue. Living cells were quantified using a
hemacytometer. These observations and the cell counting
protocol were carried out in triplicate for each growth condition.
Cell fractionation and 3C protease localization
To prepare cytoplasmic and nuclear soluble protein fractions
from 3C protease expressing cells, cells were cultured in either
in 6-well plates or 100 mm dishes to 70 to 80% confluency and
induced with ponasterone A in the presence of 25 μM MG132
as described above. For each fractionation, cells from four to six
wells, for 6-well plates, or 6 to 12 100 mm dishes were
trypsinized, pelleted by centrifugation for 2 min at 1300×g, and
washed twice with 10 volumes of cold PBS. The cytoplasmic
and nuclear lysate soluble protein fractions were obtained using
the NE-PER nuclear and cytoplasmic extraction reagents
following the manufacturer's protocol and were immediately
frozen in aliquots at − 80 °C. The protein concentrations of the
fractions were determined using the Bradford reagent.
The cytoplasmic and nuclear fractions were tested for the
presence of the expressed 3C protease by subjecting 20 μg of
protein from each fraction to SDS-PAGE and Western blotting
as described above. G3PDH and PARP were used as
cytoplasmic or nuclear markers, respectively, and were detected
in the blots using anti-G3PDH or anti-PARP monoclonal
antibodies and anti-mouse IgG alkaline phosphatase conjugated
secondary antibodies via the same procedures described above.
To examine nuclear extract fractions for the presence of
polyubiquitin-EMCV 3C protease conjugates, 100 μg aliquots
of nuclear fraction protein were mock immunoprecipitated,
without antibody, or immunoprecipitated with anti-3C protease
antibody. The precipitates were subjected to SDS-PAGE and
Western blotting using anti-3C protease or anti-ubiquitin
primary antibodies and alkaline phosphatase-conjugated sec-
ondary antibodies. The blots were developed using the ECF
alkaline phosphatase reagent as described above.
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